September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 11, 2025

COVID Exits Top 10 as US Deaths Fall

Age-adjusted US death rate fell 3.8% in 2024, the lowest since 2020, provisional data show

Conexiant

September 10, 2025

Medical Societies Challenge Kennedy

"That you can no longer trust the recommendations out of the CDC is just devastating."

Conexiant

September 10, 2025

Should Kids With Lice Stay in Class?

Debate continues over school head lice policies as parents call for stricter exclusion rules while public health guidance supports in-class management.

KFF Health News

September 08, 2025

FDA Expands Indications for Von Willebrand Disease

FDA expands Vonvendi to adult routine prophylaxis (types 1 and 2) and pediatric on-demand/perioperative use.

Conexiant

September 03, 2025

FDA Approves Denosumab Biosimilars

The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.

Conexiant

September 03, 2025

CDC Leadership Changes May Impact Vaccine Guidance

Leadership changes at the CDC could affect vaccine guidance and public health policy, with potential implications for physicians and patient care.

KFF Health News

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant